- Home
- SGHT vs CRBU Comparison
SGHT vs CRBU Comparison
Compare SGHT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- CRBU
- Stock Information
- Founded
- SGHT 2011
- CRBU 2011
- Country
- SGHT United States
- CRBU United States
- Employees
- SGHT N/A
- CRBU N/A
- Industry
- SGHT Medical Specialities
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- SGHT Health Care
- CRBU Health Care
- Exchange
- SGHT Nasdaq
- CRBU Nasdaq
- Market Cap
- SGHT 140.1M
- CRBU 151.2M
- IPO Year
- SGHT 2021
- CRBU 2021
- Fundamental
- Price
- SGHT $2.53
- CRBU $1.31
- Analyst Decision
- SGHT Buy
- CRBU Strong Buy
- Analyst Count
- SGHT 7
- CRBU 5
- Target Price
- SGHT $4.68
- CRBU $11.80
- AVG Volume (30 Days)
- SGHT 195.9K
- CRBU 1.3M
- Earning Date
- SGHT 03-05-2025
- CRBU 03-10-2025
- Dividend Yield
- SGHT N/A
- CRBU N/A
- EPS Growth
- SGHT N/A
- CRBU N/A
- EPS
- SGHT N/A
- CRBU N/A
- Revenue
- SGHT $79,543,000.00
- CRBU $11,475,000.00
- Revenue This Year
- SGHT $1.23
- CRBU N/A
- Revenue Next Year
- SGHT $0.34
- CRBU N/A
- P/E Ratio
- SGHT N/A
- CRBU N/A
- Revenue Growth
- SGHT N/A
- CRBU N/A
- 52 Week Low
- SGHT $2.50
- CRBU $1.22
- 52 Week High
- SGHT $8.45
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- SGHT 35.62
- CRBU 39.05
- Support Level
- SGHT $2.59
- CRBU $1.30
- Resistance Level
- SGHT $2.87
- CRBU $1.46
- Average True Range (ATR)
- SGHT 0.18
- CRBU 0.09
- MACD
- SGHT 0.02
- CRBU 0.02
- Stochastic Oscillator
- SGHT 6.74
- CRBU 33.33
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.